Fondaparinux in the management of patients with ST-elevation acute myocardial infarction

References

• AgnelliGBergqvistDCohenATRandomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgeryBr J Surg20059212122016175516
   PubMed Web of Science ®Google Scholar
• AlexanderKPChenAYRoeMTExcess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromesJAMA200529431081616380591
   PubMed Web of Science ®Google Scholar
• AntmanEMAnbeDTArmstrongPWACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)Circulation2004110e8229215339869
   PubMed Web of Science ®Google Scholar
• AntmanEMMorrowDAMcCabeCHEnoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarctionN Engl J Med200635414778816537665
   PubMed Web of Science ®Google Scholar
• BauerKAErikssonBILassenMRFondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgeryN Engl J Med200134513051011794149
   PubMed Web of Science ®Google Scholar
• BéguinSChoayJHemkerHCThe action of a synthetic pentasaccharide on thrombin generation in whole plasmaThromb Haemost1989613974012799755
   PubMed Web of Science ®Google Scholar
• BullerHRDavidsonBLDecoususHSubcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolismN Engl J Med2003349169570214585937
   PubMed Web of Science ®Google Scholar
• BullerHRDavidsonBLDecoususHFondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trialAnn Intern Med20041408677315172900
   PubMed Web of Science ®Google Scholar
• CohenATDavidsonBLGallusASEfficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trialBMJ2006332325916439370
   PubMed Web of Science ®Google Scholar
• CohenMGensiniGFMaritzFThe safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trialJ Am Coll Cardiol20034213485614563573
   PubMed Web of Science ®Google Scholar
• CollinsRPetoRBaigentCSleightPAspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarctionN Engl J Med1997336847609062095
   PubMed Web of Science ®Google Scholar
• CoussementPKBassandJPConvensCA synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE studyEur Heart J20012217162411511121
   PubMed Web of Science ®Google Scholar
• DonatFDuretJPSantoniAThe pharmacokinetics of fondaparinux sodium in healthy volunteersClin Pharmacokinet200241Suppl1912383039
   PubMed Web of Science ®Google Scholar
• EagleKAGoodmanSGAvezumAPractice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE)Lancet2002359373711844506
   PubMed Web of Science ®Google Scholar
• EikelboomJWAnandSSMalmbergKUnfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysisLancet200035519364210859038
   PubMed Web of Science ®Google Scholar
• EikelboomJWMehtaSRAnandSSAdverse impact of bleeding on prognosis in patients with acute coronary syndromesCirculation20061147748216908769
   PubMed Web of Science ®Google Scholar
• EikelboomJWQuinlanDJMehtaSRUnfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trialsCirculation200511238556716344381
   PubMed Web of Science ®Google Scholar
• ErikssonBIBauerKALassenMRFondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgeryN Engl J Med2001345129830411794148
   PubMed Web of Science ®Google Scholar
• HerbertJMPetitouMLormeauJCSR 90107/Org 31540, a novel anti-factor Xa antithrombotic agentCardiovasc Drug Rev199715126
   Web of Science ®Google Scholar
• LassenMRBauerKAErikssonBIPostoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparisonLancet200235917152012049858
   PubMed Web of Science ®Google Scholar
• MehtaSRStegPGGrangerCBArixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot TrialCirculation20051111390715781750
   PubMed Web of Science ®Google Scholar
• MoscucciMFoxKACannonCPPredictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE)Eur Heart J20032418152314563340
   PubMed Web of Science ®Google Scholar
• RaoSVO’GradyKPieperKSImpact of bleeding severity on clinical outcomes among patients with acute coronary syndromesAm J Cardiol2005961200616253582
   PubMed Web of Science ®Google Scholar
• RaoSVO’GradyKPieperKSA comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromesJ Am Coll Cardiol2006478091616487850
   PubMed Web of Science ®Google Scholar
• SilberSAlbertssonPAvilesFFGuidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyEur Heart J2005268044715769784
   PubMed Web of Science ®Google Scholar
• SimoonsMLBobbinkIWBolandJA dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes; The Pentasaccharide in Unstable Angina (PENTUA) studyJ Am Coll Cardiol20044321839015193678
   PubMed Web of Science ®Google Scholar
• SmithSCJrFeldmanTEHirshfeldJWJrACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention)Circulation2006113e16628616490830
   PubMed Web of Science ®Google Scholar
• SpiessBDRoystonDLevyJHPlatelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomesTransfusion2004441143815265117
   PubMed Web of Science ®Google Scholar
• [ASSENT] The Assessment of the Safety and Efficacy of New Thrombolytic Regimen (ASSENT)-3 InvestigatorsEfficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarctionLancet20013586051311530146
   PubMed Web of Science ®Google Scholar
• TherouxPFusterVAcute coronary syndromes: unstable angina and non-Q-wave myocardial infarctionCirculation19989711952069537346
   PubMed Web of Science ®Google Scholar
• TurpieAGThe safety of fondaparinux for the prevention and treatment of venous thromboembolismExpert Opin Drug Saf200547072116011449
   PubMedGoogle Scholar
• TurpieAGBauerKAErikssonBIPostoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trialLancet2002a3591721612049860
   PubMed Web of Science ®Google Scholar
• TurpieAGBauerKAErikssonBIFondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studiesArch Intern Med2002b16218334012196081
   PubMed Web of Science ®Google Scholar
• TurpieAGGallusASHoekJAPentasaccharide InvestigatorsA synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacementN Engl J Med20013446192511228275
   PubMed Web of Science ®Google Scholar
• van de WerfFArdissinoDBetriuAManagement of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of CardiologyEur Heart J200324286612559937
   PubMed Web of Science ®Google Scholar
• WhiteHHirulog and Early Reperfusion or Occlusion (HERO)-2 Trial InvestigatorsThrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trialLancet200135818556311741625
   PubMed Web of Science ®Google Scholar
• YusufSMehtaSRChrolaviciusSComparison of fondaparinux and enoxaparin in acute coronary syndromesN Engl J Med2006a35414647616537663
   PubMed Web of Science ®Google Scholar
• YusufSMehtaSRChrolaviciusSEffects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trialJAMA2006b29515193016537725
   PubMed Web of Science ®Google Scholar
• YusufSMehtaSRXieCEffects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevationJAMA20052934273515671427
   PubMed Web of Science ®Google Scholar